DGAP-Adhoc: BB Biotech AG closes the 2019 fiscal year with a profit
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Preliminary Results
BB Biotech AG closes the 2019 fiscal year with a profit
17-Jan-2020 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Media Release, January 17, 2020
BB Biotech AG closes the 2019 fiscal year with a profit
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its fiscal year 2019.
BB Biotech AG closed its fiscal year 2019 with a profit of approximately CHF 677 million, based on its preliminary unaudited consolidated results (CHF 471 million loss in the previous year).
As an investment company, the results reflect the performance of the stocks BB Biotech AG holds in its investment portfolio.
The publication of all relevant portfolio data will take place on January 17, 2020 at 7:00 am and the complete annual report will be published on February 21, 2020.
For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, [email protected]
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
17-Jan-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
BB BIOTECH AG |
|
Schwertstrasse 6 |
|
8200 Schaffhausen |
|
Switzerland |
Phone: |
+41 52 624 08 45 |
E-mail: |
[email protected] |
Internet: |
www.bbbiotech.ch |
ISIN: |
CH0038389992 |
WKN: |
A0NFN3 |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX |
EQS News ID: |
955315 |
|
End of Announcement |
DGAP News Service |
955315 17-Jan-2020 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
624,17 |
5,13 |
669,48 |
683,90 |
0,00 |
1,28 |
0,57 |
EBITDA1,2 |
588,33 |
-418,21 |
624,04 |
637,31 |
-390,46 |
-361,02 |
-222,29 |
EBITDA-Marge3 |
94,26 |
-8.152,24 |
93,21 |
93,19 |
0,00 |
-28.204,69 |
|
EBIT1,4 |
588,33 |
-418,21 |
624,04 |
637,31 |
-390,46 |
-361,02 |
-222,29 |
EBIT-Marge5 |
94,26 |
-8.152,24 |
93,21 |
93,19 |
0,00 |
-28.204,69 |
-38.998,25 |
Jahresüberschuss1 |
587,80 |
-418,27 |
622,84 |
637,24 |
-390,53 |
-362,83 |
-222,41 |
Netto-Marge6 |
94,17 |
-8.153,41 |
93,03 |
93,18 |
0,00 |
-28.346,09 |
-39.019,30 |
Cashflow1,7 |
225,26 |
95,66 |
197,69 |
241,97 |
-91,44 |
234,37 |
234,97 |
Ergebnis je Aktie8 |
10,62 |
-7,55 |
11,24 |
11,51 |
-7,05 |
-6,59 |
-4,05 |
Dividende8 |
2,85 |
2,68 |
3,20 |
3,32 |
3,67 |
2,88 |
2,58 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Deloitte
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
BB Biotech |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A0NFN3 |
47,200 |
Kaufen |
2.614,88 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
33,71 |
5,42 |
6,11 |
115,66 |
KBV |
KCV |
KUV |
EV/EBITDA |
1,10 |
11,13 |
4.587,51 |
-11,76 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
2,88 |
2,10 |
4,45 |
21.03.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
26.04.2024 |
26.07.2024 |
25.10.2024 |
16.02.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-2,71% |
6,90% |
3,28% |
-5,98% |
|
|